GaryStevenSachsMD
Psychiatry • Boston, MAAddiction
Associate Clinical Professor of Psychiatry, Massachusetts General Hospital
Dr. Sachs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
50 Staniford st
Suite 580
Boston, MA 02114Phone+1 617-724-4639Fax+1 617-726-6768- Is this information wrong?
Education & Training
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1983 - 1986
University of Maryland/Sheppard PrattResidency, Psychiatry, 1982 - 1982
University of Maryland School of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1988 - Present
MA State Medical License 1984 - 2025
FL State Medical License 2019 - 2021
MD State Medical License 1983 - 1983- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Start of enrollment: 1998 Sep 01
- A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression Start of enrollment: 2008 Nov 01
Publications & Presentations
PubMed
- Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward.William P Horan, Dawn I Velligan, Richard S E Keefe, Florence Butlen-Ducuing, Philip D Harvey, Gary Sachs, Michael Davis, Ni A Khin> ;Innovations in Clinical Neuroscience. 2024 Mar 1
- 1 citationsCariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-B...Robert Riesenberg, Paul P Yeung, Ludmyla Rekeda, Gary S Sachs, Majid Kerolous, Maurizio Fava> ;The Journal of Clinical Psychiatry. 2023 Aug 16
- 6 citationsAdjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.Gary S Sachs, Paul P Yeung, Ludmyla Rekeda, Arifulla Khan, Julie L Adams, Maurizio Fava> ;The American Journal of Psychiatry. 2023 Mar 1
- Join now to see all
Press Mentions
U.S. FDA Approves VRAYLAR® (Cariprazine) as an Adjunctive Treatment for Major Depressive DisorderDecember 17th, 2022- Antipsychotic Safe, Effective for Resistant Depression in Phase 3 TrialMay 26th, 2022
- Add-on Vraylar Tied to Easing of Recurrent Depressive SymptomsMay 22nd, 2022
- Join now to see all
Grant Support
- Pilot Study Of A Calcium Channel Blocker In FemalesNational Institute Of Mental Health1999–2000
- Treatment Of Bipolar DisorderNational Institute Of Mental Health1998–2000
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
